SPOTLIGHT -
Shared perspectives on the role of continued therapy in patients with transplant-ineligible newly diagnosed multiple myeloma in light of clinical data and dose adjustment strategies.
Recap: MRD Negativity, Frailty, and Emerging Therapies in Multiple Myeloma
An expert panel highlights novel therapeutic approaches for newly diagnosed and relapsed multiple myeloma.
Between the Lines™ Podcast: Updates in Use of Proteasome Inhibitors for Relapsed/Refractory Multiple Myeloma
Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.
Recap: Mayo and Moffitt Face-Off in Myeloma Data Presentation
Experts from the Mayo Clinic and Moffitt Cancer Center go head-to-head to discuss recent data in multiple myeloma and updates from recent meetings.
Oncology Peer Review On-The-Go: Treatment Considerations for Transplant-Ineligible Multiple Myeloma
CancerNetwork®’s podcast dives into an article focused on treatment options for older, transplant-ineligible patients with multiple myeloma.
Ide-cel and kidney disease: the re(n)al-world experience with BCMA CAR-T
Rahul Banerjee, MD, FACP, discusses a recent presentation from the Tandem meeting regarding BCMA CAR T-cell therapy in patients with multiple myeloma.
FDA Grants Priority Review to Elranatamab for R/R Multiple Myeloma
The FDA and European Medicines Agency accept applications for elranatamab for relapsed or refractory multiple myeloma.